Faster Production Of Panbela's Pancreatic Cancer Drug

Transforming a complex, low-yield synthesis into a streamlined, scalable process can be the difference between stalled development and clinical progress. By rethinking the route design for a pancreatic cancer therapy, significant gains were achieved in efficiency, chiral purity, and manufacturability. The approach combined alternative starting materials, innovative reaction pathways, and targeted removal of unnecessary steps to reduce overall process burden. Enhanced analytical methods ensured precise measurement of chiral purity while supporting regulatory alignment. Eliminating chromatography and introducing more cost-effective reagents further accelerated production timelines and simplified scale-up. The result is a robust, GMP-ready process that not only improves output quality but also positions the therapy for sustained clinical and commercial advancement.

Explore how strategic process redesign can unlock measurable improvements across development and manufacturing.